Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;31(3):306-314.
doi: 10.1016/j.beha.2018.07.010. Epub 2018 Jul 17.

Peripheral T-cell lymphoma - are we making progress?

Niloufer Khan  1 , Neval Ozkaya  2 , Alison Moskowitz  3 , Ahmet Dogan  4 , Steven Horwitz  5
Affiliations
Review

Peripheral T-cell lymphoma - are we making progress?

Niloufer Khan et al. Best Pract Res Clin Haematol. 2018 Sep.

Abstract

Peripheral T cell lymphoma (PTCL) is a rare subtype of non-Hodgkin lymphoma. PTCLs are heterogeneous in terms of biology, but generally have more aggressive features and poorer outcomes than aggressive B-cell lymphomas when treated with combination chemotherapy. While the best long-term results are still seen with intensive chemotherapeutic approaches, significant progress has been made with molecular profiling identifying genetic drivers of PTCL that could serve as therapeutic targets. Tailoring therapy to different subtypes of PTCL may lead to more individualized approaches with the hope of improved outcomes. In this paper, we review current therapies for treatment of PTCL, newly identified molecular markers, and the role of emerging therapy and novel combinations of existing agents.

Keywords: Gene expression profiling; Immunotherapy; Lymphoma; Peripheral; T-cell.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement:

Dr. Khan has received research support from Gilead Sciences.

Dr. Ozkaya has no conflict of interest.

Dr. Moskowitz receives research support from Seattle Genetics, Incyte, BMS, and Merck.

She has received honorarium and consulting fees from Seattle Genetics.

Dr Dogan receives consulting fees from Novartis, Celgene, Seattle Genetics, and Corvus Pharmaceuticals.

Dr. Horwitz receives research support from Celgene, Millenium/Takeda, Kyowa-Hakka-Kirin, Seattle Genetics, Forty-Seven, Infinity/Verastem, ADCT Therapeutics, Aileron Therapeutics, and Trillium. He has received consulting fees from Millenium/Takeda,Kyowa-Hakka-Kirin, Seattle Genetics, Forty-Seven, Mundipharma, Aileron, ADCT, Portola and Innate Pharma.

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editor. Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed.: Lyon: International Agency for Research on Cancer; 2017.
    1. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23. - PMC - PubMed
    1. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63. - PubMed
    1. Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. The American journal of surgical pathology. 2009;33(5):682–90. - PMC - PubMed
    1. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. The New England journal of medicine. 2012;366(1):95–6. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources